Erythropoietin or Darbepoetin for patients with cancer - meta-analysis based on individual patient data

ESA treatment in cancer patients increased on study mortality and worsened overall survival. For patients undergoing chemotherapy the increase was less pronounced, but an adverse effect could not be excluded.